The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale Total Score (p ≤0.021 and p ≤0.542, respectively) Roluperidone separated from placebo on both primary and key secondary endpoints at Weeks 4, 8 and 12 Roluperidone was generally well tolerated with a safety profile
May 29, 2020
· 7 min read